Randomised, double-masked, controlled trial of intravitreal Avastin (bevacizumab) versus Triesence (triamcinolone) at the time of cataract surgery on the visual outcomes for patients with diabetic macular oedema

Royal Victorian Eye and Ear Hospital0 个研究点目标入组 100 人开始时间: 2011年8月19日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Clinically significant macular oedema involving the fovea of the study eye at baseline OR which has occured within 24 months of study entry OR microaneurysms within the foveal avascular zone which are not amenable to treatment with laser
•Cataract in the study eye which requires extraction in the opinion of the investigator

•Glaucoma with visual field defects or uncontrolled glaucoma
•Past history of intraocular pressure rise >35mmHg following steroid treatment
•Significant macular ischemia
•Visual acuity of <6/60 in the fellow eye
•Known allergies to the study medications
•Systemic treatment with steroids >5mg prednisolone (or equivalent) daily
•Intercurrent severe systemic disease or ocular infection
•Women of childbearing potential not using adequate contraception or women who are breastfeeding
•Intravitreal triamcinolone within 10 weeks of study entry
•Intravitreal Avastin within 3 weeks of study entry
•Argon laser photocoagulation within 3 months prior to study entry

发起方

Royal Victorian Eye and Ear Hospital